Cue Health’s Post

The role of trimethoprim/sulfamethoxazole in preventing opportunistic infections in systemic lupus erythematosus patients receiving low-level immunosuppressive treatment: an open-label, randomized, controlled trial The Role of Trimethoprim/Sulfamethoxazole in Preventing Infections in SLE Patients Study Overview This study focused on patients with systemic lupus erythematosus (SLE) who are at risk for infections while receiving low-level immunosuppressive treatment. The goal was to see if trimethoprim/sulfamethoxazole (TMP/SMX) could help prevent these infections. Methodology The trial was conducted at Ramathibodi Hospital from May 2021 to December 2022. SLE patients were randomly assigned to receive either TMP/SMX or no treatment. Researchers monitored infection rates and side effects over 12 months. Results The trial ended early due to a high rate of side effects linked to TMP/SMX. Out of 138 patients, none developed infections, but 14.3% experienced adverse drug reactions (ADRs). Most reactions were mild, but some were more severe, leading patients to stop the treatment. Conclusions Over the 12 months, no infections were found in patients taking TMP/SMX, indicating that this treatment may not provide significant benefits for SLE patients on low-level immunosuppressive therapy. The high rate of side effects highlights the need for careful evaluation by healthcare providers. Practical Solutions and Value Clinical trials are essential for developing safe treatments. Our AI-driven platform, DocSym, helps integrate clinical standards and research into a user-friendly tool for healthcare providers. This makes it easier to manage patient care through scheduling, treatment monitoring, and telemedicine. By leveraging AI, clinics can streamline operations, improve patient outcomes, and reduce reliance on paper processes. Discover how we can assist you at aidevmd.com. https://lnkd.in/gtsH_T-v #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Infections are a major cause of morbidity in children with primary or secondary immunodeficiency, and have a negative impact on overall outcome. In this up-to date narrative review you will find paediatric-specific aspects on the clinical impact, diagnosis, management, and follow-up of infectious complications in in this vulnerable population.

Candidemia Following Severe COVID‐19 in Hospitalised and Critical Ill Patients: A Systematic Review and Meta‐Analysis - Authors include our Olivia Kates https://lnkd.in/eQ7_EHYS

🚨 New Publication Alert 🚨 We commend Jansen et al. for their recent publication, “Central-line-associated bloodstream infection (CLABSI) burden among Dutch neonatal intensive care units,” which provides an insightful epidemiological overview of CLABSIs in Dutch neonatal intensive care units. 📊🩺 However, it's crucial to recognize that while the article focuses on central catheters, short-term peripheral intravenous catheters (PIVCs) are commonly used and can also lead to significant complications. Although the incidence of bloodstream infections from PIVCs is lower, their widespread use means they may contribute to a higher total number of infections compared to central catheters. Moreover, PIVC-related injuries, such as infiltration, can significantly impact patient well-being. Therefore, peripherally inserted central catheters (PICCs) may be a safer alternative, balancing the need for effective vascular access with a lower risk of complications.  In conclusion, while the article by Jansen et al. enriches our understanding of CLABSI epidemiology, a broader exploration of preventative strategies involving the entire spectrum of vascular access devices, including PIVCs and PICCs, is warranted. This approach deepens our understanding of catheter-related complications (like bloodstream infections) and empowers clinicians to prioritize patient safety and therapeutic efficacy. 📚 Original articles: - [DOI: 10.1016/j.jhin.2023.11.020](https://lnkd.in/dkAjNiRb) - [DOI: 10.1016/j.jhin.2024.03.024](https://lnkd.in/dGdMcWYr)

In a survey of PCPs and GI-Hep providers across 5 US safety-net health systems, knowledge gaps and perceived barriers to HCC surveillance were identified, which can targeted with educational interventions to improve HCC surveillance in cirrhosis patients. https://ja.ma/3UOs9f4

When a large children's hospital acquired multiplex GI panels, they hoped to reduce hospital-onset C. difficile infections (HO-CDI), C. difficile detection and overall stool testing by 20% within the first year. What happened next was even more exciting: ✅ HO-CDI decreased by 55% ✅ C. difficile detection decreased by 44% ✅ $55,649 annually savings in stool testing–all with no adverse events for their patients Syndromic solutions like the BIOFIRE® FILMARRAY® Gastrointestinal Panel don't just support your patient care, it can also help your organization save unnecessary costs! The early publication report is out now: https://bit.ly/48N7sVs Learn why our customers call the BIOFIRE GI Panel an "absolutely essential" tool in their clinical practice: https://bit.ly/3wMmdLa

I share today the letter we published in 2017 proposing the concept of Pre-Sepsis as a necessary (and still absent) definition to early detect patients with infection in transition to sepsis, published in J Crit Care.. https://lnkd.in/dSuXT28i

Exciting news for the healthcare industry! DCN Dx has received FDA De Novo marketing authorization for the Cepheid Xpert Hepatitis C Virus (HCV) test, marking a significant breakthrough in HCV diagnosis. This innovative test is the first point-of-care HCV RNA test that can deliver results in about an hour using a fingertip blood sample. The Cepheid Xpert HCV test represents a game-changing approach to HCV diagnosis and treatment. It enables a test-and-treat strategy where patients can be tested, diagnosed, and potentially begin treatment during a single healthcare visit. This streamlined process has the potential to dramatically improve HCV detection and treatment rates, addressing a critical gap in current healthcare practices. Key benefits of this new test include: 🔸 Rapid results in about one hour 🔸 Use in CLIA-waived settings, including substance use disorder treatment facilities and correctional facilities 🔸 Potential to diagnose and treat hundreds of thousands more HCV patients 🔸 Reduced risk of patients being lost to follow-up As Dr. Jeff Shuren, director of the FDA's Center for Devices and Radiological Health, noted, this test could be instrumental in combating the spread of HCV and improving patient outcomes. With an estimated 2.4 to 4 million people living with HCV in the United States, this authorization represents a significant step forward in public health efforts to address this widespread infection. https://lnkd.in/endstgzV 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCar #HealthcareInnovation #HepatitisC #PointOfCareTesting

Just shared an interesting perspective from an article on the overuse of ESR and CRP tests in infectious disease management. Despite their widespread use, these tests show limited diagnostic accuracy and clinical utility for infections, especially when ordered routinely. The article challenges the "zombie" nature of these tests, which continue to be used out of habit rather than necessity. It's a great reminder to practice diagnostic stewardship: focusing on using the right test for the right patient to prompt the right action 🦠💊 Thanks to the amazing ID team Brad Spellberg, Bassam Ghanem Pharm.D ,MS,BCPS #Diagnostics #InfectiousDiseases #Healthcare #Pharmacy #Stewardship

After news today of FDA approval for the first at-home, over the counter syphilis test to combat rising rates of this sexually transmitted infection, I asked ChatGPT: "What would Shantanu Nundy, MD, say about the new syphilis at-home diagnostic test?" Response: "Dr. Shantanu Nundy, known for his interest in digital health and innovative approaches to healthcare, would likely view a new at-home syphilis test with cautious optimism. He might emphasize the potential benefit of increasing access to testing and improving early detection. However, he would also likely stress the importance of ensuring accuracy, proper use, and follow-up care. He might advocate for integrating such tests into a broader healthcare strategy to ensure that individuals receive appropriate treatment and support if they test positive." +1 chatGPT! https://lnkd.in/ecfWY5Ys